| 239 | 8 | 108 |
| 下载次数 | 被引频次 | 阅读次数 |
目的通过药物利用评价(DUE)方法评价某院比阿培南临床应用情况,为促进临床合理使用比阿培南提供参考。方法随机抽取2015年7月至2017年6月使用比阿培南的187例病历,依据建立的DUE标准进行回顾性分析。结果 (1)用药指征:适应证符合标准率98. 4%,有禁忌证占5. 3%;(2)用药过程:实验室指标监测符合标准率62. 0%(生命体征、病原学、全血和白细胞、肝肾功能监测符合率标准分别为100%、80. 7%、82. 4%、82. 9%),有用药相互作用的占4. 3%,用法用量、溶媒、特殊人群、疗程和联合用药符合标准率100%;(3)用药结果:治疗有效率85. 6%,不良反应监测符合标准率95. 2%;(4)管理指标:病程记录符合标准占95. 7%,会诊、处方权符合率100%。结论比阿培南的临床使用存在一定问题和不足,建立比阿培南DUE标准可用于规范比阿培南的临床使用。
Abstract:AIM To evaluate the clinical utilization of biapenem in a hospital with drug use evaluation( DUE),and provide reference for rational use of biapenem. METHODS On a basis of biapenem DUE criteria,a retrospective analysis was made in 187 hospitalized patients with biapenem in the hospital from July 2015 to June2017. RESULTS(1)Medication indication: the coincidence rate of medication indication was 98. 4%,and contraindication rate was 5. 3%;(2) Medication process: laboratory indicators rate was 62. 0%( the coincidence rate of vital signs was 100%,etiological examination was 80. 7%,blood monitoring was 82. 4%,liver and kidney function monitoring was 82. 9%),the drug interaction rate was 4. 3%,the medication usage and dosage,solvent selection,special crowd,course of treatment and drug combination rate were 100%;(3)Medication results: the treatment effective rate was 85. 6% and adverse drug reaction monitoring rate was 95. 2%;(4)Management indicators:the coincidence rate of progress notes was 95. 7% and consultation,prescribing authority was 100%. CONCLUSION There are some inappropriate medication problems in biapenem utilization in the hospital. Established DUE criteria possesses of biapenem can standardize the clinical utilization of biapenem.
[1]杜晓明,姜继国,穆晓攀.新一代碳青霉烯类抗菌药比阿培南[J].中国药师,2014,17(7):1234.
[2]李明艳,吴洪文.比阿培南研究进展[J].医药导报,2014,33(3):352.
[3]KEMPF M,ROLAIN J M,AZZA S,et al. Investigation of Acinetobacter baumannii resistance to carbapenems in Marseille hospitals,south of France:a transition from an epidemic to an endemic situation[J]. APMIS,2013,121(1):64.
[4] American Society of Health-System Pharmay. ASHP Guidelines on Medication-Use Evaluation[J]. Am J Health-Syst Pharm,2014,169.
[5]袁浩宇,林勇,胡明,等.药物利用评价标准建立的方法探讨及实践[J].中国药房,2010(22):2101.
[6]史天陆,孙言才,姜玲,等.比阿培南临床合理使用评价标准的建立与应用[J].中华医院感染学杂志,2012,22(23):5367.
[7]柏蓉,袁红宇,张晓兰,等.比阿培南的药物利用评价分析及干预措施[J].药学与临床研究,2015(4):410.
[8]张楠,陆红柳,杨慧鹃,等.某院碳青霉烯类抗菌药物的临床应用调查与用药合理性评估[J].中国药房,2016,27(29):4047.
[9]黄艳芳,吴柳婷,罗洁丽,等.亚胺培南药物利用评价标准的建立及应用[J].中国药房,2016(2):271.
[10]王桂凤,李雪芹,刘锐锋,等.某院替加环素药物利用评价标准的建立与应用分析[J].中国药房,2017,28(14):1892.
[11]佟青,张一兵,白璐.某医院治疗性使用抗菌药物患者病原学标本送检与检测结果分析[J].中国消毒学杂志,2015,32(7):669.
[12]TORII M,TAKIGUCHI Y,SAITO F,et al. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats[J]. J Pharm Pharmacol,2001,53(6):823.
[13] MANCL E,GIDAL B. The effect of carbapenem antibiotics on plasma concentrations of valproic acid[J]. Ann Pharmacother,2009,43(12):2082.
[14]MASUO Y,ITO K,YAMAMOTO T,et al. Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide[J]. Drug Metab Dispos,2010,38(10):1828.
[15] PARK M,LIM K,KIM T,et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics:overview of 6 cases[J]. Ther Drug Monit,2012,34(5):599
[16]唐莲,庄智伟,赵富丽,等.比阿培南与美罗培南对丙戊酸血药浓度影响的比较研究[J].药物不良反应杂志,2015,17(2):126.
[17]LISTED N. ASHP guidelines on the pharmacist's role in the development,implementation,and assessment of critical pathways[J].Am J Health Syst Pharm,2004,61(9):939.
基本信息:
DOI:10.19577/j.1007-4406.2018.05.011
中图分类号:R969.3
引用信息:
[1]王丽昕,王可可,李玲,等.比阿培南药物利用评价标准的建立及应用[J].中国临床药学杂志,2018,27(05):338-342.DOI:10.19577/j.1007-4406.2018.05.011.
基金信息:
苏州市科技发展计划(编号SYSD2015145)
2018-09-25
2018-09-25